It has been a long-time coming. It has been hyped and scoffed, bet against and hoped for, but now none of that matters. It's here. Dendreon has brought Provenge to market. Here, in the word's of the FDA...
For Immediate Release: April 29, 2010
FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer
The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.
Provenge is indicated for the treatment of asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment.
Prostate cancer is the second most common type of cancer among men in the United States, behind skin cancer, and usually occurs in older men. In 2009, an estimated 192,000 new cases of prostate cancer were diagnosed and about 27,000 men died from the disease, according to the National Cancer Institute.
“The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available,” said Karen Midthun, M.D., acting director of the FDA’s Center for Biologics Evaluation and Research.
Provenge is an autologous cellular immunotherapy, designed to stimulate a patient’s own immune system to respond against the cancer. Each dose of Provenge is manufactured by obtaining a patient’s immune cells from the blood, using a machine in a process known as leukapheresis. To enhance their response against the cancer, the immune cells are then exposed to a protein that is found in most prostate cancers, linked to an immune stimulating substance. After this process, the patient’s own cells are returned to the patient to treat the prostate cancer. Provenge is administered intravenously in a three-dose schedule given at about two-week intervals.
The effectiveness of Provenge was studied in 512 patients with metastatic hormone treatment refractory prostate cancer in a randomized, double-blind, placebo-controlled, multicenter trial, which showed an increase in overall survival of 4.1 months. The median survival for patients receiving Provenge treatments was 25.8 months, as compared to 21.7 months for those who did not receive the treatment.
Almost all of the patients who received Provenge had some type of adverse reaction. Common adverse reactions reported included chills, fatigue, fever, back pain, nausea, joint ache and headache. The majority of adverse reactions were mild or moderate in severity. Serious adverse reactions, reported in approximately one quarter of the patients receiving Provenge, included some acute infusion reactions and stroke. Cerebrovascular events, including hemorrhagic and ischemic strokes, were observed in 3.5 percent of patients in the Provenge group compared with 2.6 percent of patients in the control group.
Provenge is manufactured by Seattle-based Dendreon Corp.
- Stem cells for a Webby! [Last Updated On: August 18th, 2024] [Originally Added On: April 28th, 2010]
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: August 18th, 2024] [Originally Added On: April 30th, 2010]
- Google to Invest in Regenerative Medicine [Last Updated On: August 18th, 2024] [Originally Added On: May 5th, 2010]
- Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 [Last Updated On: August 18th, 2024] [Originally Added On: May 22nd, 2010]
- The changing face of PR and why it matters to regenmed [Last Updated On: August 18th, 2024] [Originally Added On: June 12th, 2010]
- FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 18th, 2024] [Originally Added On: August 12th, 2010]
- Careers in cell therapy & regenerative medicine [Last Updated On: August 18th, 2024] [Originally Added On: October 11th, 2010]
- Careers in cell therapy & regenerative medicine [Last Updated On: August 18th, 2024] [Originally Added On: October 11th, 2010]
- The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: August 18th, 2024] [Originally Added On: February 14th, 2011]
- Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: August 18th, 2024] [Originally Added On: February 14th, 2011]
- In vivo cell trafficking just took a leap forward [Last Updated On: August 18th, 2024] [Originally Added On: July 3rd, 2011]
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: August 18th, 2024] [Originally Added On: July 10th, 2011]
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: August 18th, 2024] [Originally Added On: July 10th, 2011]
- Clinical trial costs [Last Updated On: August 18th, 2024] [Originally Added On: July 31st, 2011]
- Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 18th, 2024] [Originally Added On: August 14th, 2011]
- Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: August 18th, 2024] [Originally Added On: September 18th, 2011]
- Commercial-stage Cell Therapy Companies and Products [Last Updated On: August 18th, 2024] [Originally Added On: September 18th, 2011]
- Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: August 18th, 2024] [Originally Added On: September 25th, 2011]
- Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: August 18th, 2024] [Originally Added On: September 25th, 2011]
- Commercializing Cell-based Regenerative Medicines [Last Updated On: August 18th, 2024] [Originally Added On: November 13th, 2011]
- Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: August 18th, 2024] [Originally Added On: November 27th, 2011]
- Active phase III or II/III cell therapy trials [Last Updated On: August 18th, 2024] [Originally Added On: December 11th, 2011]
- Recently approved cell therapy products [Last Updated On: August 18th, 2024] [Originally Added On: December 18th, 2011]
- Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: August 18th, 2024] [Originally Added On: December 18th, 2011]
- 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: August 18th, 2024] [Originally Added On: January 1st, 2012]
- Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline? [Last Updated On: August 18th, 2024] [Originally Added On: March 11th, 2012]
- Another > $100M month for companies in the cell therapy space [Last Updated On: August 18th, 2024] [Originally Added On: May 6th, 2012]
- Another > $100M month for companies in the cell therapy space [Last Updated On: August 18th, 2024] [Originally Added On: May 6th, 2012]
- Cell-based Cancer Immunotherapies. Some metrics.. [Last Updated On: August 18th, 2024] [Originally Added On: May 20th, 2012]
- Industry-sponsored cardiovascular cell therapies. Some metrics. [Last Updated On: August 18th, 2024] [Originally Added On: May 27th, 2012]
- Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing [Last Updated On: August 18th, 2024] [Originally Added On: June 17th, 2012]
- FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012) [Last Updated On: August 18th, 2024] [Originally Added On: July 29th, 2012]
- Is the cell therapy sector outperforming the major indices? [Last Updated On: August 18th, 2024] [Originally Added On: August 12th, 2012]
- Are some cell counts too good to be true? Why some companies' product data may mislead. [Last Updated On: August 18th, 2024] [Originally Added On: September 2nd, 2012]
- Are some cell counts too good to be true? Why some companies' product data may mislead. [Last Updated On: August 18th, 2024] [Originally Added On: September 2nd, 2012]
- Two lessons I learned this week. [Last Updated On: August 18th, 2024] [Originally Added On: September 16th, 2012]
- The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. [Last Updated On: August 18th, 2024] [Originally Added On: September 30th, 2012]
- Anticipated short-term cell therapy industry clinical milestones [Last Updated On: August 18th, 2024] [Originally Added On: September 30th, 2012]
- The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. [Last Updated On: August 18th, 2024] [Originally Added On: September 30th, 2012]
- Cell therapy portfolio outperforms major indices year-to-date [Last Updated On: August 18th, 2024] [Originally Added On: October 14th, 2012]
- CIRM addresses some tough questions. Is it all just glass towers and basic research? [Last Updated On: August 18th, 2024] [Originally Added On: October 21st, 2012]
- GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. [Last Updated On: August 18th, 2024] [Originally Added On: November 4th, 2012]
- GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. [Last Updated On: August 18th, 2024] [Originally Added On: November 4th, 2012]
- Cell Therapy Industry Group Welcomes its 4,000th member [Last Updated On: August 18th, 2024] [Originally Added On: November 11th, 2012]
- Six steps to fighting non-compliant cell therapy treatments. --- The stuff of grey shades, spades, ivory towers and (ahem) balls. [Last Updated On: August 18th, 2024] [Originally Added On: December 2nd, 2012]
- A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments [Last Updated On: August 18th, 2024] [Originally Added On: December 16th, 2012]
- The ROI on pant-wearing and other social media tips [Last Updated On: August 18th, 2024] [Originally Added On: December 16th, 2012]
- The Accuracy of Adipose Stem Cell Doses [Last Updated On: August 18th, 2024] [Originally Added On: December 23rd, 2012]
- Cell Therapy Blog welcomes 2013 [Last Updated On: August 18th, 2024] [Originally Added On: January 6th, 2013]
- 2013 Annual Regenerative Medicine Industry Report [Last Updated On: August 18th, 2024] [Originally Added On: April 21st, 2013]
- Commercialization of Regenerative Medicine: Learning from Spin-Outs [Last Updated On: August 18th, 2024] [Originally Added On: April 28th, 2013]